1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882


Delayed London Stock Exchange  -  05/23 11:35:11 am EDT
1782.00 GBX   +1.02%
05/20Deutsche Bank Keeps GSK At Hold, Boosts PT
05/19GLAXOSMITHKLINE : Deutsche Bank remains Neutral
05/19GLAXOSMITHKLINE PLC : Ex-dividend day for interim dividend
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Trian expected to revive its P&G playbook with Unilever

01/25/2022 | 09:43am EDT
FILE PHOTO: FILE PHOTO: Nelson Peltz founding partner of Trian Fund Management LP. speak at the WSJD Live conference in Laguna Beach, California

BOSTON (Reuters) - Two and a half years ago Nelson Peltz, the billionaire activist investor who often presents himself as a partner with constructive advice for companies, told an audience of pension and hedge funds that no one had a monopoly on good ideas.

Sitting only a few feet away, nodding in agreement, was Procter & Gamble Co Chief Executive David Taylor, who ended one of the industry's most acrimonious corporate battles by inviting Peltz onto P&G's board in 2018.

For nearly four years until Peltz' retirement from the P&G board in August, the men traded ideas about how to woo new customers to buy Tide detergent and Pampers diapers. Since Trian first invested with P&G, the company's stock price nearly doubled.

Now Peltz' Trian Fund Management has built a stake in P&G rival Unilever Plc, the purveyor of Dove and Lifebuoy soap, Hellmann's mayonnaise and Knorr bouillon, according to several sources. Trian has declined to confirm the stake and declined to comment for this story.

A half a dozen bankers and lawyers who have worked with Peltz for roughly a decade and watched him operate at a number of large companies expect he may soon bring the playbook that worked at Cincinnati-based P&G to Unilever's London-based CEO Alan Jope.

"It is not that Nelson Peltz has a deep grounding in soap, but he knows his way around complex companies," said an advisor who knows how Trian works but is not permitted to discuss the private firm publicly. "His team can work backwards from an income statement to understand what levers need to be pulled to make a company better."

Unilever declined to comment.

At P&G, Trian criticized aging brands, a "suffocating bureaucracy," short term thinking and sluggish shareholder returns. Many of the same problems https://www.reuters.com/business/unilevers-soap-opera-ma-job-cuts-grumpy-investors-2022-01-25 exist at Unilever, where the share price has been roughly flat for years. The company last week suffered a stinging rejection https://www.reuters.com/business/retail-consumer/unilever-offers-50-bln-pounds-gsk-unit-report-2022-01-15 when GlaxoSmithKline refused to sell it its consumer health unit, bankers said.

Unilever has already taken some steps to cut costs by consolidating its headquarters in London and getting rid of some slower growing businesses like its Lipton tea brand. Unilever, which employs about 149,000 people worldwide, on Tuesday said it plans to cut about 1,500 management jobs https://www.reuters.com/business/retail-consumer/unilever-cut-1500-management-jobs-strategic-overhaul-2022-01-25 in a restructuring to create five product-focused divisions - a revamp that echoes P&G's reshaping three years ago https://www.reuters.com/article/us-procter-gamble-strategy-idUKKCN1ND37M.

But bankers and analysts said there is more work ahead at Unilever, such as winning in the digital marketplace and solving for an insular culture in which many top executives, including the CEO, have worked for decades. Unilever's sluggish sales that have been largely blamed on the pandemic, coupled with a drop in operating profits for the full 2021 year, leave room for improvement, bankers said.

The half dozen people who have known how Trian operates said the firm has shaped itself into an operational activist that sticks around for many years to see the job through. It has previously taken stakes in Mondelez and Pepsico as well as General Electric, where it has been an investor since 2015.

Trian likes to present itself as an additional resource to the board and often signals that it does not want to replace others. But once inside the boardroom, two of the insiders also said that Trian's voice often takes over and crowds out others.

Trian's army of analysts work relentlessly on producing binders of information and data to help the board and management think through new ways of doing things, the people said.

While investors and bankers said Trian may use a model for what it wants done at a company, they also said there is little fear of corporate secrets leaking because the principals, and even the entire firm, tend to sign non-disclosure agreements to ensure confidentiality.

The firm's team works largely out of the limelight and its three founders rarely make public demands to fire the chief executive as some other activists do, bankers and analysts said. Trian's most recent public investments have been in mutual fund companies Invesco and JanusHenderson.

(Reporting by Svea Herbst-Bayliss; Additional reporting by Richa Naidu; editing by Vanessa O'Connell and Edward Tobin)

By Svea Herbst-Bayliss

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
GENERAL ELECTRIC COMPANY 0.28% 75.46 Delayed Quote.-20.12%
GLAXOSMITHKLINE PLC 1.02% 1782 Delayed Quote.10.92%
INVESCO LTD. 0.70% 18.7 Delayed Quote.-18.77%
LIMELIGHT NETWORKS, INC. 0.57% 3.52 Delayed Quote.2.62%
MONDELEZ INTERNATIONAL, INC. 1.39% 62.04 Delayed Quote.-6.44%
PEPSICO, INC. 2.09% 165.6 Delayed Quote.-4.67%
PROCTER & GAMBLE COMPANY 2.30% 145.05 Delayed Quote.-11.33%
THE WENDY'S COMPANY 0.24% 16.66 Delayed Quote.-30.15%
UNILEVER PLC 0.50% 3534 Delayed Quote.-10.30%
05/20Deutsche Bank Keeps GSK At Hold, Boosts PT
05/19GLAXOSMITHKLINE : Deutsche Bank remains Neutral
05/19GLAXOSMITHKLINE PLC : Ex-dividend day for interim dividend
05/18S&P Maintains GSK's Ratings, Stable Outlook on Expected Post-Demerger Recovery
05/17FTSE 100 lags European peers on strong pound
05/17GlaxoSmithKline Pharmaceuticals Sees Surge in Fiscal Q4 Consolidated Net Profit
05/16Glaxosmithkline Confirms It Has Changed Its Name To GSK PLC
05/16GlaxoSmithKline Adopts Shortened GSK Name
05/16GlaxoSmithKline plc has Changed its Name to GSK plc
05/16SocGen Lifts GlaxoSmithKline's PT, Keeps Buy Rating
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Sales 2022 36 527 M 45 926 M 45 926 M
Net income 2022 5 289 M 6 650 M 6 650 M
Net Debt 2022 17 655 M 22 198 M 22 198 M
P/E ratio 2022 16,8x
Yield 2022 2,95%
Capitalization 90 190 M 113 B 113 B
EV / Sales 2022 2,95x
EV / Sales 2023 2,80x
Nbr of Employees 90 096
Free-Float 93,6%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 1 782,00 GBX
Average target price 1 865,77 GBX
Spread / Average Target 4,70%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Hal V. Barron Executive Director & Chief Scientific Officer
Jon Ellis VP & Head-Technology Business Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.89%465 705
PFIZER, INC.-10.45%294 404
ABBVIE INC.9.33%266 851
ROCHE HOLDING AG-15.67%266 707